Evidence map›Paper›PMID 40649625›Full record

ArticleMaterials (Basel, Switzerland)2025

Effect of Ni-Based Superalloy on the Composition and Lifetime of Aluminide Coatings.

Maryana Zagula-Yavorska

Abstract read
In one paragraph

Article in Materials (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Maryana Zagula-YavorskaFaculty of Mechanical Engineering and Aeronautics, Rzeszow University of Technology, al. Powstańców Warszawy 12, 35-959 Rzeszów, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aluminide coatings on nickel-based superalloys were synthesized via a high-temperature "clean" low-activity vapor-phase process. This process is environmentally friendly and meets manufacturers' environmental protection requirements. Hence, it fulfils the Industry 4.0 requirements, where the reduction of environmental impact in the industrial sector is a key issue. Surface morphology, cross-section microstructure, and phase composition of the coatings were studied and compared by using an optical microscope and a scanning electron microscope (SEM) equipped with an energy dispersive spectroscope (EDS) and X-ray diffraction (XRD). Bare and coated superalloys' lifetime was evaluated and compared via air exposure at 1100 °C. High-temperature low-activity aluminizing of the IN713, IN625, and CMSX4 superalloys enabled the obtainment of the desirable β-NiAl phase. The highest nickel content in the chemical composition of the IN713 superalloy among the investigated superalloys resulted in the highest aluminide coatings' thickness. Moreover, the higher refractory elements concentration in the IN625 and CMSX4 superalloys than that in the IN713 superalloy may contribute to a thinner aluminide coatings' thickness. Refractory elements diffused to the surface of the superalloy and formed carbides or intermetallic phases, which impeded outward nickel diffusion from the substrate to the surface and thereby inhibited coating growth. The obtained coatings fulfilled the requirements of ASTM B 875. Despite the fact that the coating formed on IN713 was thicker than that formed on IN625, the lifetime of both coated superalloys was comparable. Oxidation resistance of the aluminide coatings formed on the IN713 and IN625 superalloys makes them the favored choice for gas turbine applications.

Indexed as

air exposurehigh-temperature low-activity vapor-phase processinterplanar distance of the β-NiAl phaserefractory elements

Identifiers

PMID40649625
PMCPMC12251511

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.